HDAC9 and breast cancer: HDAC inhibitors, such as sodium butyrate, panobinostat, and vorinostat, which can impair DNA repair, suppress the escape of MCF7 cells from DNA damage response and cell death program and exert cytotoxic effects on metastatic breast cancer cells by inhibiting the EMT signaling pathway [214,215,216].